Wegovy's Next Step: Novo Nordisk Eyes Approval for Higher-Dose Treatment

benzinga.com/news/fda/25/09/47692734/wegovys-next-step-novo-nordisk-eyes-approval-for-higher-dose-treatment

Novo Nordisk A/S (NYSE:NVO) reportedly said on Tuesday that it intends to seek US regulatory approval for a high-dose version of its weight-loss injection Wegovy (semaglutide), another effort to counter Eli Lilly and Co. (NYSE:LLY).
Martin Holst Lange, chief scientific officer at Novo…

This story appeared on benzinga.com, 2025-09-16 14:21:36.
The Entire Business World on a Single Page. Free to Use →